Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab

PURPOSE: The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual anti-human epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized that high...

Descripción completa

Detalles Bibliográficos
Autores principales: Ha, Joo Young, Kim, Jeong Eun, Lee, Hee Jin, Jeong, Jae Ho, Ahn, Jin-Hee, Jung, Kyung Hae, Gong, Gyungyub, Chae, Eun Young, Kim, Hak Hee, Chung, Il Yong, Ko, Beom Seok, Kim, Sung-Bae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410619/
https://www.ncbi.nlm.nih.gov/pubmed/34352937
http://dx.doi.org/10.4048/jbc.2021.24.e36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410619/
https://www.ncbi.nlm.nih.gov/pubmed/34352937
http://dx.doi.org/10.4048/jbc.2021.24.e36

Ejemplares similares